INNOVACAP vs PPLPHARMA: Stock Comparison

Innova Captab Limited vs Piramal Pharma Limited

Live data: 27 July 2026, 4:08 PM IST • Source: NSE and company filings

Piramal Pharma Limited is the larger company by market capitalisation. Innova Captab Limited shows a higher ROE, a higher dividend yield and faster revenue growth, while Piramal Pharma Limited shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Innova Captab Limited and Piramal Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, INNOVACAP is more favourable on 11 of 13 scored metrics and PPLPHARMA on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PPLPHARMA is the larger company
₹25,562 Cr vs ₹5,528 Cr
P/E Ratio
PPLPHARMA has a lower P/E
-78.29x vs 39.59x
P/B Ratio
PPLPHARMA has a lower P/B
3.12x vs 5.12x
EPS
INNOVACAP has higher earnings per share
₹24.62 vs ₹-2.45
Dividend Yield
INNOVACAP has a higher dividend yield
0.42% vs 0.08%
Revenue Growth (TTM YoY)
INNOVACAP has faster revenue growth
42.3% vs -0.1%
EPS Growth (TTM YoY)
INNOVACAP has faster EPS growth
28.6% vs 0%
Qtr Sales Growth
INNOVACAP has stronger quarterly sales growth
42.3% vs -0.08%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINNOVACAPPPLPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINNOVACAPPPLPHARMA
Live Price₹970.4₹192.05
Day Change2.1%5.95%
Volume43,7361.52 Cr
52-Week High₹1,034.85₹210.5
52-Week Low₹622₹132.3
Distance from 52W High-6.23%-8.76%

Valuation

MetricINNOVACAPPPLPHARMA
Market Cap₹5,528 Cr₹25,562 Cr
P/E Ratio39.59x-78.29x
P/B Ratio5.12x3.12x
EPS₹24.62₹-2.45
Book Value₹190.62₹64.78
Dividend Yield0.42%0.08%

Growth

MetricINNOVACAPPPLPHARMA
Revenue Growth (TTM YoY)42.3%-0.1%
EPS Growth (TTM YoY)28.6%0%
Qtr Sales Growth42.3%-0.08%
Qtr Profit Growth28.8%-25%

Profitability & Leverage

MetricINNOVACAPPPLPHARMA
ROE13.7%-3.83%
ROCE15%2.52%
Net Margin8.65%-3.68%
Operating Margin14.9%10.4%
Debt to Equity0.32x0.7x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINNOVACAPPPLPHARMA
Promoter Holding50.9%34.8% 0.06 pp
FII Holding0.34% 0.11 pp12.52% 17.66 pp
DII Holding19.92% 0.22 pp14.57% 1.04 pp
Public Holding28.84% 0.11 pp37.63% 18.62 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Innova Captab Limited and Piramal Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.